MDxHealth (MDXH.BR): Research Note

MDxHealth  is a market leader in the fast growing field of molecular testing focused on identification of DNA or RNA imprints, which can turn a healthy cell into a cancer cell. The main commercial focus of the Company is on urologic cancers. 

research clients

Please contact us if you are interested in research on either of these companies or on other companies in our universe. 

Resverlogix (RVX.TO): Initiating Coverage Report 

Resverlogix is a clinical stage cardiovascular company with an epigenetic platform technology that modulates protein production. The company is the first to test the BET inhibition hypothesis as a new approach for reducing major adverse cardiovascular events (MACE) in high risk diabetes and CKD patients.

Galapagos (GPLG.BR): Research Note 

Galapagos announced that its JAK1 inhibitor filgotinib (GLPG0634) met its primary and secondary endpoints after 12 weeks of treatment in the socalled DARWIN in moderate to severe RA patients 

Invion Group (INV.AX): Research Note 

Invion Group is an Australian based biotech company focused on the development of treatments for large indications in respiratory disease and autoimmune disease. The company has three drug assets in development, with three FDA-regulated, phase II clinical trials and two preclinical feasibility studies currently ongoing. 

Latest Research

Our client base consists of pubic traded companies in Europe, North America and Australia. The total universe of biotechnology companies that we follow on a daily basis comprises around 200 companies. 


CLIENTS



Biofrontera (B8F.DE): Research Note

Biofrontera AG (B8F.DE, B8F.L) is a biopharmaceutical company specializing in the development of dermatological drugs. Its lead product is Ameluz®, a prescription drug approved for use in Europe for the treatment of mild to moderate actinic keratosis (AK) on the face and scalp in conjunction with photodynamic therapy (PDT). 

Immuron (IMC.AX): Initiating Coverage Report

Immuron Ltd is a publicly listed Australian biopharmaceutical company focused on oral immunotherapy utilizing polyclonal antibody products that target the human gut immune system. Its lead program is IMM-124E which is currently in Phase II for fatty liver-diseases NASH (non-alcoholic steatohepatitis) and ASH (alcoholic steatohepatitis). Its second program, IMM-529, is in development to target the Clostridium difficile  bacterium. We have increased our valuation calculation following a rerating of both its programs in NASH and CDI. Especially in NASH, the potential deal size has increased following recent activity in the area. In our view, the company’s current total value should be AUD 197 million, or AUD 1.92 per share compared to our previous calculation of AUD 75 million. 

Anteo Diagnostics (ASX:ADO): Initiating Coverage

Anteo Diagnostics (ASX: ADO) is an Australia based medical technology company that provides scientists in the Life Sciences, In Vitro Diagnostic (IVD), Medical Device and Energy markets with powerful tools developed with its patented core nanotechnology.